Navigation Links
Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
Date:5/20/2009

FRAZER, Pa., May 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it intends to offer, subject to market and other conditions, $300 million of common stock and $350 million in aggregate principal amount of convertible senior subordinated notes due 2014 through two concurrent public offerings. Cephalon will grant the underwriters a 30-day option, solely to cover over-allotments, to purchase up to an additional $45 million of common stock, with respect to the common stock offering, and to purchase up to an additional $52.5 million in aggregate principal amount of the notes, with respect to the notes offering.

The notes will be convertible into cash and, if applicable, shares of Cephalon's common stock based on a conversion rate to be determined. The interest rate, conversion price and other terms of the notes will be determined at the time of pricing of the offering by negotiations between Cephalon and the underwriters. The notes will be subordinate to existing and future senior indebtedness, equal to existing and future senior subordinated indebtedness and senior in right of payment to existing and future subordinated indebtedness of Cephalon.

The offerings are being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. For each offering, a prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the U.S. Securities and Exchange Commission. Neither of these offerings is contingent upon the consummation of the other offering.

Cephalon intends to use a portion of the net proceeds of the notes offering to enter into a hedging transaction on its common stock with Deutsche Bank AG, London Branch (the "hedge counterparty"), an affiliate of the representative
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cephalons New Product Launches Pace Record 2008 Sales
2. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
3. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
4. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
5. Cephalon, Inc. to Webcast Analyst Day
6. Cephalon Reports Another Strong Quarter
7. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
8. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
9. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
10. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
11. Cephalon Quarterly Conference Call Invitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... ... Probiotics has released a case study that provides a sustainable solution ... evidence of the effectivness of beneficial microbial applications. These results are ... Environmental Protection Agency, who recently agreed to identify and investigate ...
... ... in new product launch of Chewy Bite Line expansion to include one of a kind ... Las Vegas, ... keep up with the demand to learn more about their new products at the ASMBS ...
... As previously announced on October 24th, 2009 delSECUR sold 100% ... Ontario company, QTECH SYSTEMS INC. in exchange for 49% of shares ... QTECH,s Management Team and the appointment of a new Chief Technology Officer, ... , , ...
Cached Biology Technology:Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... neonatal abstinence syndrome (NAS) secondary to in-utero opioid ... withdrawal than others, but the underlying reasons are ... genes are turned on or off) changes have ... Boston University School of Medicine (BUSM) and Boston ... kind study to identify some of these epigenetic ...
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... the ongoing mission to train and educate scientists on ... J. Craig Venter Institute,s (JCVI) Eukaryotic Genome Annotation and ... to train 40 United States Agriculture Department (USDA) scientists ... session will focus on the use of JCVI,s eukaryotic ...
... Langone Medical Center may have discovered a new targeted ... disease, is a serious genetic disorder occurring predominantly in ... childhood. The new study entitled, "Role of calcium-independent phospholipase ... published in the Proceedings of the National Academy ...
... to the successful implantation of a fertilized human egg. ... of the implantation can all affect the outcome of ... University researcher is suggesting that prospective parents and their ... other biomechanical processes play in its success. New studies ...
Cached Biology News:JCVI program trains USDA scientists on eukaryotic genome analysis 2New potential therapeutic target discovered for genetic disorder -- Barth syndrome 2Engineering bouncing babies, 1 at a time 2
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
...
Biology Products: